These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 31197505)

  • 1. Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia.
    Nóbrega C; Mendonça L; Marcelo A; Lamazière A; Tomé S; Despres G; Matos CA; Mechmet F; Langui D; den Dunnen W; de Almeida LP; Cartier N; Alves S
    Acta Neuropathol; 2019 Nov; 138(5):837-858. PubMed ID: 31197505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The stress granule protein G3BP1 alleviates spinocerebellar ataxia-associated deficits.
    Koppenol R; Conceição A; Afonso IT; Afonso-Reis R; Costa RG; Tomé S; Teixeira D; da Silva JP; Côdesso JM; Brito DVC; Mendonça L; Marcelo A; Pereira de Almeida L; Matos CA; Nóbrega C
    Brain; 2023 Jun; 146(6):2346-2363. PubMed ID: 36511898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
    Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
    Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model.
    Toonen LJA; Overzier M; Evers MM; Leon LG; van der Zeeuw SAJ; Mei H; Kielbasa SM; Goeman JJ; Hettne KM; Magnusson OT; Poirel M; Seyer A; 't Hoen PAC; van Roon-Mom WMC
    Mol Neurodegener; 2018 Jun; 13(1):31. PubMed ID: 29929540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The blood-brain barrier is disrupted in Machado-Joseph disease/spinocerebellar ataxia type 3: evidence from transgenic mice and human post-mortem samples.
    Duarte Lobo D; Nobre RJ; Oliveira Miranda C; Pereira D; Castelhano J; Sereno J; Koeppen A; Castelo-Branco M; Pereira de Almeida L
    Acta Neuropathol Commun; 2020 Aug; 8(1):152. PubMed ID: 32867861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
    Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
    Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
    PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease.
    Nascimento-Ferreira I; Santos-Ferreira T; Sousa-Ferreira L; Auregan G; Onofre I; Alves S; Dufour N; Colomer Gould VF; Koeppen A; Déglon N; Pereira de Almeida L
    Brain; 2011 May; 134(Pt 5):1400-15. PubMed ID: 21478185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
    Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
    J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics.
    Paulino R; Nóbrega C
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice.
    Nguyen HP; Hübener J; Weber JJ; Grueninger S; Riess O; Weiss A
    PLoS One; 2013; 8(4):e62043. PubMed ID: 23626768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3.
    Griffin JL; Cemal CK; Pook MA
    Physiol Genomics; 2004 Feb; 16(3):334-40. PubMed ID: 14679302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy.
    Watchon M; Yuan KC; Mackovski N; Svahn AJ; Cole NJ; Goldsbury C; Rinkwitz S; Becker TS; Nicholson GA; Laird AS
    J Neurosci; 2017 Aug; 37(32):7782-7794. PubMed ID: 28687604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Far-infrared Radiation Improves Motor Dysfunction and Neuropathology in Spinocerebellar Ataxia Type 3 Mice.
    Liu SW; Chang JC; Chuang SF; Liu KH; Cheng WL; Chang HJ; Chang HS; Lin TT; Hsieh CL; Lin WY; Hsieh M; Kuo SJ; Liu CS
    Cerebellum; 2019 Feb; 18(1):22-32. PubMed ID: 29725949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy Function and Benefits of Autophagy Induction in Models of Spinocerebellar Ataxia Type 3.
    Watchon M; Luu L; Plenderleith SK; Yuan KC; Laird AS
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
    Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
    Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Olfactory Ensheathing Cell Transplantation Improves Motor Function in a Mouse Model of Type 3 Spinocerebellar Ataxia.
    Hsieh J; Liu JW; Harn HJ; Hsueh KW; Rajamani K; Deng YC; Chia CM; Shyu WC; Lin SZ; Chiou TW
    Cell Transplant; 2017 Oct; 26(10):1611-1621. PubMed ID: 29251109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes.
    Haas E; Incebacak RD; Hentrich T; Huridou C; Schmidt T; Casadei N; Maringer Y; Bahl C; Zimmermann F; Mills JD; Aronica E; Riess O; Schulze-Hentrich JM; Hübener-Schmid J
    Mol Neurobiol; 2022 Jan; 59(1):495-522. PubMed ID: 34716557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
    Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
    Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation.
    Chou AH; Chen YL; Hu SH; Chang YM; Wang HL
    Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.